Dr. Hornberger's recent and current funding includes projects sponsored by county, state, and federal government agencies (National Institutes of Health, Agency for Health Research and Quality, Department of Veterans Affairs, Health Resources and Services Administration, and the U.S. Office of Technology Assessment), professional medical societies (Renal Physicians Association), nonprofit agencies and foundations (Picker Foundation and Salt Lake City Health Access Program), and for-profit companies (Roche Pharmaceuticals, Roche Laboratories, and Genentech, Inc.).
Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma†
Article first published online: 8 MAR 2005
Copyright © 2005 American Cancer Society
Volume 103, Issue 8, pages 1644–1651, 15 April 2005
How to Cite
Hornberger, J. C. and Best, J. H. (2005), Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer, 103: 1644–1651. doi: 10.1002/cncr.20956
The development of the model and the subsequent analyses were supported by a grant from Genentech, Inc. The sponsors of the study had no role in the model design, cost-utility analysis, or interpretation of the results. All investigators had unlimited access to the model and data. No limitations on publication were imposed. The authors made the final decisions on all analyses presented in the article.
- Issue published online: 4 APR 2005
- Article first published online: 8 MAR 2005
- Manuscript Accepted: 10 DEC 2004
- Manuscript Revised: 9 NOV 2004
- Manuscript Received: 17 AUG 2004
- Genentech, Inc.
- 1American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society, Inc., 2002.
- 9Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood). 2004 (Suppl Web Exclusives): W4-284–W4-296..
- 122005 UpToDate® online 12.3. Available from URL: http://www.uptodate.com [accessed December 13, 2004]., . Treatment of highly aggressive non-Hodgkin's lymphomas.
- 14Physican's Desk Reference Staff. 2003 Drug topics (R) red book. Montvale, NJ: Thomson PDR, 2003.
- 20http://www.asco.org/ac/1,1003,_12-002643-00_18-0016-00_19-002639,00asp [accessed December 13, 2004]., , , et al. Quality-of-life (QoL) in patients treated with rituximab as a single agent [abstract 2693]. Presented at the 2002 Annual Meeting of the American Society of Clinical Oncology. Available from URL:
- 21Quality of life (QOL) in elderly patients with aggressive non-Hodgkin's lymphoma (NHL) treated with CHOP [abstract 1803]. Blood. 2001; 98: 430a., , , , .
- 22Hodgkin's disease and non-Hodgkin's lymphoma. In: BlackR, StocktonD, editors, for the Scottish Executive Health Department. Cancer scenarios: an aid to planning cancer services in Scotland in the next decade. Edinburgh: The Scottish Executive, 2001. Chapter sections in HTML format available from URL: http://www.show.scot.nhs.uk/sehd/publications/csatp/csatp-20.htm [accessed December 13, 2004]..
- 24Time preference. In: GoldMR, SiegellJE, RussellL, WeinsteinM, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214–246., , .
- 34GELA. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors. Presented at the 2003 Annual Meeting of the American Society of Clinical Oncology. Abstract and Microsoft® Powerpoint slides available from URL: http://www.asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-001570,00.asp [accessed December 13, 2004]., , et al. for
- 36Report on State of the Art in Blood and Marrow Transplantation: The 2003 BMT summary slides with guide. From the Center for International Blood and Marrow Transplant Research. Newsletter 2004; 10(2). PDF and Microsoft® Powerpoint slides available from URL: http://www.ibmtr.org/newsletter/newsletter_sums.html [accessed December 13, 2004].